

Covidien plc
Form 425
August 29, 2014

Stockholm Investor Meetings
August 29, 2014
Ryan Weispfenning
Senior Director, Investor Relations
ryan.weispfenning@medtronic.com

Edgar Filing: Covidien plc - Form 425

Jeff Warren

Vice President, Investor Relations

jeff.warren@medtronic.com

Filed by Medtronic, Inc. (SEC File No.: 001-07707)

pursuant to Rule 425 under the Securities Act of 1933

and deemed filed pursuant to Rule 14a-12

under the Securities Exchange Act of 1934

Subject Company: Covidien plc

Form S-4 File No.: 333-197406

Date: August 29, 2014

1
|
Stockholm
Investor
Meetings

August
29,

2014

Medtronic Positioned to Execute
Creating Long-Term Value in Healthcare

Improving operational execution to
deliver consistent results

Uniquely positioned to expand our
market-leading franchises through
three differentiated strategies:

Combining reliable performance with
disciplined capital allocation to create
long-term shareholder value

1.

Therapy Innovation: Delivering strong
launch cadence of meaningful
therapies and procedures

2.

Globalization: Addressing the inequity
in healthcare access globally

3.

Economic Value: Becoming a leader
in value-based healthcare by
incorporating EV into our DNA

2
|
Stockholm
Investor
Meetings

August
29,

2014
Medtronic Today
CoreValve
Evolut
R
MiniMed®
530G
Viva
CRT-D
Advisa MRI
Cardiac and
Vascular Group
Restorative
Therapies Group
Diabetes
Resolute
Integrity
Endurant®
II
PVAC®
GOLD
Solera®
Milestone
Knee
Restore®
Sensor
PEAK®
PlasmaBlade
FY14
Revenue:
\$17.0B
Pumps and Sensors
TAVR
Atrial
Fibrillation
Pacing
Defibrillation
DES
AAA
Core Spine
Pain Stim
Ortho
Advanced
Energy
1. On a constant currency basis. Reflects Medtronic on a stand-alone
MDT Financial Formula
Revenue
Growth
1
Mid-Single

Digits
Operating &
Financial
Leverage
EPS Growth
1
200
400 bps
Faster than
Revenue
Dividend Yield
~200 bps
Total
Shareholder
Return
High-Single to
Double Digits
basis and does not include Covidien.
AAA

Adjusted
EPS
Delivering on Commitments
And Strengthening our Competitive Position
Highlights
FY14
Actual
FY14

Guidance

Free Cash

Flow

Revenue

Growth

+3 -

4%

\$4 -

\$4.5B

+3.6%

\$4.6B

\$3.80 -

\$3.85

\$3.82

Returned 50%+ to shareholders

\$2.6B share repurchases

50bps of operating leverage

FY14 Emerging Markets growth of 14%

Meaningful product launches including
the MiniMed®

530G, Reveal LINQ

and CoreValve®

Established Cardiocom®

and Cath Lab

Managed Services (CLMS) as future
growth platforms

Effective tax management

Unhedged currency and U.S.

device tax

1.

On an operational basis.

2.

Non-GAAP diluted EPS.

3.

Free cash flow defined as operating cash flow minus capital expenditures.

Note: All revenue figures assume constant currency. Non-GAAP reconciliation available in Appendix & on Medtronic's website

2

3

TM

1

3

|

Stockholm

Investor

Meetings

August

29,

2014

Medtronic Q1 FY15 Financial Results
Reported on August 19, 2014

Overall, Q1 represented balanced growth, with strong performances in some areas offset by challenges in others

US markets driving growth: grew
+6%, the highest growth in the US in
5 years

New therapies contributed 200bps
to overall growth driven by Reveal
LINQ, CoreValve, and MiniMed 530G

Our robust pipeline will contribute
significantly to our future growth

Breadth and scale having an
increasing advantage: Focused on
New Therapies, Economic Value, and
Globalization

Revenue

\$4.3 billion

% Growth, as reported

+5%

% Growth, constant FX

+4%

GAAP Net Earnings

\$871 million

% Growth

-9%

GAAP Diluted EPS

\$0.87

% Growth

-6%

Non-GAAP Net Earnings

\$934 million

% Growth

+4%

Non-GAAP Diluted EPS

\$0.93

% Growth

+6%

Cash EPS

\$0.99

% Growth

+5%

1 On a constant currency basis

Note: Non-GAAP reconciliation available in Appendix & on Medtronic's website
at www.medtronic.com

4 |

Stockholm

Investor

Meetings

August

29,
2014

5 | Stockholm
Investor
Meetings

August
29,
2014
Therapy

Innovation
Globalization
Economic
Value
GROWTH VECTOR #1:
GROWTH VECTOR #2:
GROWTH VECTOR #3:
Medtronic Growth Strategies
Strategies to Address Universal Healthcare Needs
Strong upcoming
launch cadence of
innovative
therapies
Unlocking massive
opportunity for
existing therapies
in emerging
markets
Leading industry
shift to value-
based healthcare
with new services
& solutions
Sources of Growth
New Therapies
Emerging
Markets
Integrated Health
Solutions
Medtronic
Strategies
Operational
Execution
Universal
HC Needs
Improve
clinical
outcomes
Expand
access
Optimize cost
and efficiency

6 |
Stockholm
Investor
Meetings

August
29,
2014

Growth Vector #1: New Therapies

Reveal LINQ

WW: Launching

IN.PACT®

Admiral®

SFA

US: By end of FY15

Micra

CE Mark: By end of FY15

FY15

Nuvent

Balloon

WW: Launching

Prestige LP

US: Launching

CoreValve®

High Risk

US: Launching

Resolute Onyx

CE: H2 FY15

FY16

O-arm®

2.0

WW: H2 FY15

Attain®

Performa

Quad

US: Launching

Select

Launches

Medtronic R&D Pipeline

1

Evolut

R

CE Mark: FY15

Next-Gen Interbodies

WW: H2 FY15

MiniMed®

640G

WE: FY15

1.

Reflects Medtronic on a stand-alone basis and does not include Covidien.

200 projects worth \$30B+ in

incremental revenue over

next 5 years

1. Moving Medtronic therapy penetration from EM level (11%) to Developed Market levels (24%) in population that can afford the therapy. Reflects Medtronic on a stand-alone basis and does not include Covidien.

EM Premium:

Attractive Opportunity

Technology already exists

Out-of-pocket payment or
reimbursement established

Comparable margins to
developed markets

~\$5B annual opportunity

Premium

Premium

Value

Value

Underserved

Underserved

Increased investment

BU and region alignment and
responsibility

Enhanced Focus &
Resources

Large scale private partnerships

Channel optimization

Public partnerships

Smarter Deployment /

Targeting

Aligning around customers

Granular focus within
countries

Go Beyond Market

Development

1

2

3

\$475

+16

%

CAG

R

\$638

EM SG&A Spend

Millions

~2,600

+33

%

CAG

R
~4,60
0
EM Headcount
Making Changes to Realize Opportunity
Growth Vector #2: Emerging Markets
7
|
Stockholm
Investor
Meetings

August
29,
2014
1

Growth Vector #3:
Integrated Health Solutions
Examples
Quantifying Value &
Expanding Offerings
Quantifying Value &
Expanding Offerings
Understand

Economic Value of
Innovation
Surgical Synergy
SM
Broaden Innovation
Time Horizon to
Ensure Value is
Realized
Collaborate and
Generate New
Business Models
Core Therapies
Wrap-Around
Services
Integrated Health
Solutions
Cath Lab
Cath Lab
Managed Services
Managed Services

AdaptivCRT®

SmartShock®
T2 Diabetes
Partnership
Rethinking Blood
Conservation (RBC®)
Bundled Payment
Pilots
8
|
Stockholm
Investor
Meetings

August
29,
2014

Growth Vectors Expected to
Deliver Mid-Single Digit Growth
Sources of Growth
GROWTH VECTOR #1
New
Therapies
GROWTH VECTOR #2
Emerging

Markets

GROWTH VECTOR #3

Integrated

Health Solutions

FY14 MDT

Growth

Contribution

180 bps

145 bps

30 bps

FY15E MDT

Growth / Contribution

+150 to 350 bps

+150 to 200 bps

+40 to 60 bps

Low-

to

Mid-Single

Mid-Teens

Double

to Triple

FY14 to FY15

Change

Mid-Term

Expectations

-30 to

+170 bps

+5 to 55 bps

+10 to 30 bps

+150 to 350 bps

+150 to 200 bps

+50 to 100 bps

TOTAL

MEDTRONIC

3.6%

3-5%

FY15 Revenue Outlook

-15 to

+255 bps

Mid-Single

Digit Growth

Note: All revenue estimates assume constant currency. Reflects Medtronic on a stand-alone basis and does not include Covidien. Non-GAAP reconciliation available in Appendix & on Medtronic's website at www.medtronic.com

9

|

Stockholm

Investor

Meetings

August
29,
2014

10
|
Stockholm
Investor
Meetings

August
29,

2014

Defensive:

Mitigate

pricing

pressure

&

maintain 75-76%

1

gross margins

Offensive:

Enable

product

tiering

&

support value segment expansion

Accomplished

Maintained

Gross Margins

Executing on Operating Expense

Reduction Initiatives

FY12

FY14:

~30

bps

reduction

FY15E

:

50 to 70 bps reduction

Improve efficiency & drive SG&A

leverage while investing in EM

1.

Forecast given on an operational basis. Reflects Medtronic on a stand-alone basis and does not include Covidien.

DRM

Mfg./Supply

Chain

New Product

Architectures

FY13-FY17:

~\$1.2B

FY08-FY12:

\$1B

FY14:

8.7%

of
revenue

FY15E:
8.5%

Shift to enhance quality systems, productivity improvements,
economic value prioritization, offsets to medical device tax
Roughly maintain level of R&D
spending going forward

Process

PRODUCT COST REDUCTION

SG&A OPERATING LEVERAGE

R&D

1

11 |
Stockholm
Investor
Meetings

August
29,
2014

S&P 500 Dividend Aristocrat
Index member; 35 years of
consecutive dividend increases

Dividend more than doubled
over the past 5 years

Over \$1 billion in dividend
payments in FY14

Payout ratio of ~30%
1

Repurchased 15% of our shares
over the past 5 years

Over \$1.2 billion in share
repurchases in FY14

Going forward, expect share
repurchase to add ~200 bps to
EPS growth annually

DIVIDENDS

SHARE REPURCHASE

Rewarding Shareholders with Distributions

Cash Priorities to Shareholders Overview

~940M

-7%

-9%

1

1.

Non-GAAP calculation based on annualized Medtronic quarterly dividend payment of \$0.305 per share as announced on June
Reflects Medtronic on a stand-alone basis and does not include Covidien.

Note: Non-GAAP reconciliation available in Appendix & on Medtronic's website at www.medtronic.com

\$0.00

\$0.40

\$0.80

\$1.20

FY00

FY01

FY02

FY03

FY04

FY05

FY06

FY07

FY08

FY09

FY10

FY11
FY12
FY13
FY14
FY15E
900
1,000
1,100
1,200
FY11
FY12
FY13
FY14
FY15E
FY16E
FY17E
FY18E

Generating Significant Free Cash Flow
\$25B+

Expected adjusted FCF generation over next 5 years equal to
40%
of
current
market

cap
1

Consistently generate > 20% FCF / revenue

Returning 50%+ of FCF to shareholders

Remain focused on improving U.S. cash

1. Based on Medtronic market capitalization as of July 29, 2014.

Note: Non-GAAP reconciliation available in Appendix & on Medtronic's website at www.medtronic.com

Adjusted free cash flow is operating cash flow minus capital expenditures. Excludes certain litigation payments. Reflects Medtronic on a stand-alone basis and does not include Covidien.

FY10-FY14

FY15-FY19E

12

|

Stockholm

Investor

Meetings

August

29,

2014

21B

\$

13
|
Stockholm
Investor
Meetings

August
29,

2014

Commitment to Return 50% of
Free Cash Flow

1

40%

\$ Billions

Corporate Use

Return to

Shareholders

~\$25B+

\$12.5B+

\$62B

\$12.5B+

Buybacks

Dividends

\$12.5B+

O.U.S.

Cash

U.S.

Cash

2. Based on Medtronic market capitalization as of July 29, 2014.

0

20

40

60

Current Market Cap

Expected Free Cash Flow,

Next 5 Years

Expected Capital

Deployment, Next 5 Years

Expected Return to

Shareholders, Next 5 Years

2

2

1.

Adjusted free cash flow is operating cash flow minus capital expenditures.

Excludes certain litigation payments. Reflects Medtronic on a stand-alone basis and does not include Covidien.

14
|
Stockholm
Investor
Meetings

August
29,

2014

Covidien Overview

Highly Strategic and Compelling Acquisition

Accelerates Medtronic's three core strategies of Therapy Innovation, Globalization, and Economic Value

Covidien's impressive portfolio of industry-leading products enhances Medtronic's portfolio, offers greater breadth across clinical areas, and creates exciting entry points into new therapies

Combination of Covidien's extensive emerging market R&D and manufacturing with Medtronic's well-established clinical expertise can be applied across a much broader product offering

Covidien's hospital efficiency technology enhances Medtronic's ability to deliver Economic Value to create a robust and unmatched Integrated Health franchise

Extremely attractive financially: Double-digit hurdle rate with achievable cost synergies

Combined
company
expected
to
generate
significant
free
cash
flow
with
greater
deployment
flexibility

Creates the Premier Global Medical Technology and Services Company with Comprehensive Product Portfolio and Broad Global Reach

Combination Results in Strategic
Diversification
COVIDIEN REVENUE
PRO FORMA REVENUE
\$17.0B
\$10.4B
\$27.4B
CRDM

Advanced
Surgical
Ortho/Spine
Peripheral &
Endovascular
Neuro

Coronary
Diabetes
Structural Heart
General

Surgical
Patient Care
Nursing Care
Patient Monitoring
Neurovascular

MEDTRONIC FY14 REVENUE

Airway &
Vent

1. Based on last 12 months, ended March 28, 2014.

29.4%

10.3%

7.1%

5.3%

17.9%

11.2%

9.2%

9.7%

CRDM

Coronary
Structural Heart
Endo

Ortho/Spine
Neuro

Surgical Tech
Diabetes

31.9%

15.2%

11.8%

10.2%

9.8%

9.5%

7.3%

4.3%

Advanced Surgical
General Surgical
Peripheral Vascular
Patient Care

Nursing Care
Patient Monitoring
Airway & Vent

Neurovascular

18.2%

17.8%

11.1%

7.7%

6.9%

6.4%

6.1%

5.8%

4.4%

3.9%

3.7%

3.6%

2.8%

1.6%

1

15

|

Stockholm

Investor

Meetings

August

29,

2014

16 |
Stockholm
Investor
Meetings

August
29,
2014

Covidien Transaction Summary

Acquisition of Covidien for \$42.9 billion in cash (\$16.1 billion) and Medtronic stock (\$26.8 billion based on Medtronic's closing stock price on June 13, 2014, the last trading day prior to the announcement of the acquisition)

Covidien shareholders to own ~30% of the combined company at closing

Cash consideration to be funded by ~\$3 billion in new debt and ~\$13 billion in cash and investments

Medtronic to assume ~\$5 billion of Covidien debt

Represents per share consideration for Covidien shareholders of:

\$35.19 in cash and 0.956 shares of new Medtronic shares

Offer represents a 29% premium to last closing share price on June 13, 2014

Transaction

Terms

Transaction

Structure

Formation of newly domiciled Irish entity; current headquarter operations remain intact in Minnesota

Transaction taxable, for U.S. federal income tax purposes, to Medtronic and Covidien shareholders

Timing

Closing expected in fourth calendar quarter of 2014 or early 2015

Subject to regulatory approvals

Subject to Medtronic and Covidien shareholder approvals

17
|
Stockholm
Investor
Meetings

August
29,

2014

Revenue Growth

Much stronger platform for diversified growth

Significant revenue synergy potential from
cross-selling

Cost Synergies

At least \$850 million pre-tax; quickly achievable

Back office optimization, manufacturing &
supply chain infrastructure, and certain G&A
savings

EPS Impact

Cash EPS accretive in FY16

Significant cash EPS accretion thereafter

GAAP EPS accretion by FY18

Balance Sheet

Implications

Significantly expands access to capital

Committed to Tier 1 commercial paper rating
Leverage

2.3x pro forma debt to EBITDA at closing

Capital Allocation

Policy

Solidifies commitment to return 50% of free
cash flow with more flexibility going forward

COMPELLING FINANCIAL IMPACT

Driving significant shareholder returns

17

|

Stockholm

Investor

Meetings

August

29,

2014

18
|
Stockholm
Investor
Meetings

August
29,

2014

Medtronic Positioned to Execute
Creating Long-Term Value in Healthcare

Improving operational execution to
deliver consistent results

Uniquely positioned to expand our
market-leading franchises through
three differentiated strategies:

1.

Therapy Innovation: Delivering strong
launch cadence of meaningful
therapies and procedures

2.

Globalization: Addressing the inequity
in healthcare access globally

3.

Economic Value: Becoming a leader
in value-based healthcare by
incorporating EV into our DNA

Combining reliable performance with
disciplined capital allocation to create
long-term shareholder value

19 |
Stockholm
Investor
Meetings

August
29,
2014

Key Websites

Global
MedTech

Leader:

<http://www.globalmedtechleader.com>

Medtronic

Investor

Relations:

<http://investorrelations.medtronic.com>

Medtronic

Covidien Key Facts

Additional Resources

20 | Stockholm
Investor
Meetings

August
29,
2014
Disclaimers

NO OFFER OR SOLICITATION

IMPORTANT ADDITIONAL INFORMATION

PARTICIPANTS IN THE SOLICITATION

Medtronic Holdings, Limited, which will be renamed Medtronic plc (New Medtronic) has filed with the Securities and Exchange Commission (SEC) a registration statement on Form S-4 that includes the preliminary Joint Proxy Statement of Medtronic, Inc. (Medtronic) (Covidien) that also constitutes a preliminary Prospectus of New Medtronic. The registration statement is not complete and Medtronic and Covidien plan to make available to their respective shareholders the final Joint Proxy Statement/Prospectus (including the Scheme) and other relevant documents filed or to be filed with the SEC. INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE PRELIMINARY JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING THE SCHEME) AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT MEDTRONIC, COVIDIEN, NEW MEDTRONIC AND RELATED MATTERS. Investors and security holders are able to obtain free copies of the preliminary Joint Proxy Statement/Prospectus (including the Scheme) and other documents filed with the SEC by New Medtronic, Medtronic and Covidien through the website maintained at www.sec.gov. In addition, investors and shareholders are able to obtain free copies of the preliminary Joint Proxy Statement/Prospectus (including the Scheme) and other documents filed by Medtronic and New Medtronic with the SEC by contacting Medtronic Investor Relations at investor.relations@medtronic.com or by calling 763-505-2696, and will be able to obtain free copies of the preliminary Joint Proxy Statement/Prospectus (including the Scheme) and other documents filed by Covidien by contacting Covidien Investor Relations at investor.relations@covidien.com or by calling 508-452-4650.

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition of securities, or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No transaction shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Medtronic, New Medtronic and Covidien and certain of their respective directors and executive officers and employees may be deemed participants in the solicitation of proxies from the respective shareholders of Medtronic and Covidien in respect of the transactions contemplated by the preliminary Joint Proxy Statement/Prospectus. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies from the respective shareholders of Medtronic and Covidien in connection with the proposed transactions, including a description of the interests, by security holdings or otherwise, will be set forth in the final Joint Proxy Statement/Prospectus when it is filed with the SEC. Information regarding Medtronic's directors and executive officers is contained in Medtronic's Annual Report on Form 10-K for the fiscal year ended September 27, 2013 and its Proxy Statement on Schedule 14A, dated July 11, 2014, which are filed with the SEC. Information regarding Covidien's directors and executive officers is contained in Covidien's Annual Report on Form 10-K for the fiscal year ended September 27, 2013 and its Proxy Statement on Schedule 14A, dated January 24, 2014, which are filed with the SEC.

21 | Stockholm
Investor
Meetings

August
29,
2014
Disclaimers (cont'd)

Cautionary Statement Regarding Forward-Looking Statements

[illegible]

Statement Required by the Irish Takeover Rules

The directors of Medtronic accept responsibility for the information contained in this document. To the best of the knowledge (who have taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with anything likely to affect the import of such information.

NO PROFIT FORECAST / ASSET VALUATIONS

No statement in this announcement is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that future earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Medtronic or any of its subsidiaries, or that any other financial results will be as appropriate. No statement in this announcement constitutes an asset valuation.

22 | Stockholm
Investor
Meetings

August
29,
2014
Non-GAAP Reconciliation Tables

Stockholm Investor Meetings
August 29, 2014

23
|
Stockholm
Investor
Meetings

August
29,

2014

Non-GAAP Reconciliation Tables

Stockholm Investor Meetings

August 29, 2014

24
|
Stockholm
Investor
Meetings

August
29,

2014

Non-GAAP Reconciliation Tables

Stockholm Investor Meetings

August 29, 2014

25
|
Stockholm
Investor
Meetings

August
29,

2014

Non-GAAP Reconciliation Tables

Stockholm Investor Meetings

August 29, 2014

26 | Stockholm
Investor
Meetings

August
29,
2014
Non-GAAP Reconciliation Tables

Stockholm Investor Meetings
August 29, 2014